CytoMed Therapeutics Begins U.S. IPO Effort


  • CytoMed Therapeutics Pte. Ltd. has filed for a U.S. IPO.
  • The firm is developing CAR-T cell approaches to treating various solid tumor cancers.
  • GDTC is still at pre-clinical stage of development, so the IPO is extremely high risk.
  • I'll provide an update when we learn more IPO information from management.
  • Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More »

Genetic engineering concept. Medical science. Scientific Laboratory.


A Quick Take On CytoMed Therapeutics Pte. Ltd.

CytoMed Therapeutics Pte. Ltd. (GDTC) has filed to raise an undisclosed amount in an IPO of its ordinary shares, according to an F-1 registration statement.

The firm is a pre-clinical

Company Financial Results

Company Financial Results (SEC)

Gain Insight and actionable information on U.S. IPOs with IPO Edge research.

Members of IPO Edge get the latest IPO research, news, and industry analysis.

Get started with a free trial!

This article was written by

Donovan Jones profile picture
Author of IPO Edge
Get IPO Edge with actionable research on next-generation high growth stocks

I'm the founder of IPO Edge on Seeking Alpha, a research service for investors interested in IPOs on US markets. Subscribers receive access to my proprietary research, valuation, data, commentary, opinions, and chat on U.S. IPOs. Join now to get an insider's 'edge' on new issues coming to market, both before and after the IPO. Start with a 14-day Free Trial.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: This report is for educational purposes only and is not financial, legal, or investment advice. The information referenced or contained herein may change, be in error, become outdated and irrelevant, or be removed at any time without notice. You should perform your own research on your particular financial situation before making any decisions. IPO investing can involve significant volatility and risk of loss.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.